NEVVI Medicare utilization intelligence

← back

DIXIT, KARANM.D. NPI 1225337017 Clinician

Hematology-Oncology · CHICAGO, IL

Specialty Hematology-Oncology — from billed Medicare claims
Trained LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE IN SHREVEPORT — medical school, self-reported to CMS
In practice about 15 years since medical school (class of 2011, self-reported to CMS)
Location CHICAGO, IL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 40 codes billed · 49,875 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
RCI (WRS) LLC
2026
NORTHWESTERN MEDICAL FACULTY FOUNDATION
2019–2026
CENTRAL DUPAGE PHYSICIAN GROUP
2022

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-05

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9380 Injection, teclistamab-cqyv, 0.5 mg
J1453 Injection, fosaprepitant, 1 mg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
J9047 Injection, carfilzomib, 1 mg
J9041 Injection, bortezomib, 0.1 mg
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J1626 Injection, granisetron hydrochloride, 100 mcg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J9190 Injection, fluorouracil, 500 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg
96372 Injection of drug or substance under skin or into muscle
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96417 Administration of additional new drug or substance into vein, 1 hour or less
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J1200 Injection, diphenhydramine hcl, up to 50 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3490 Unclassified drugs
96411 Administration of additional new drug or substance into vein using push technique
99443 Telephone medical discussion with physician, 21-30 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
36415 Insertion of needle into vein for collection of blood sample
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96374 Injection of drug or substance into vein
96377 Application of on-body injector for under skin injection

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.